Transplant outcomes after CPX-351 vs 7 + 3 in older adults with newly diagnosed high-risk and/or secondary AML

Authors

Geoffrey L Uy, Washington University School of Medicine in St. Louis
Laura F Newell, Oregon Health and Science University
Tara L Lin, University of Kansas Medical Center
Stuart L Goldberg, Hackensack University Medical Center
Matthew J Wieduwilt, University of Oklahoma
Robert J Ryan, Jazz Pharmaceuticals
Stefan Faderl, Jazz Pharmaceuticals
Jeffrey E Lancet, H. Lee Moffitt Cancer Center & Research Institute

Journal

Blood Advances

Publication Date

9-13-2022

Volume

6

Issue

17

First Page

4989

Last Page

4993

Document Type

Open Access Publication

DOI

10.1182/bloodadvances.2021006468

Rights and Permissions

Uy GL, Newell LF, Lin TL, Goldberg SL, Wieduwilt MJ, Ryan RJ, Faderl S, Lancet JE. Transplant outcomes after CPX-351 vs 7 + 3 in older adults with newly diagnosed high-risk and/or secondary AML. Blood Adv. 2022 Sep 13;6(17):4989-4993. doi: 10.1182/bloodadvances.2021006468. © 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

Recommended Citation

Uy, Geoffrey L; Newell, Laura F; Lin, Tara L; Goldberg, Stuart L; Wieduwilt, Matthew J; Ryan, Robert J; Faderl, Stefan; and Lancet, Jeffrey E, "Transplant outcomes after CPX-351 vs 7 + 3 in older adults with newly diagnosed high-risk and/or secondary AML." Blood Advances. 6, 17. 4989 - 4993. (2022).
https://digitalcommons.wustl.edu/oa_4/1381

Department

ICTS (Institute of Clinical and Translational Sciences)

Additional Links

Supplemental material is available for this article at publisher site.